AORT übertreffen die 27 der letzten 39Schätzungen.
69%
Nächster Bericht
Datum des nächsten Berichts
23. Feb. 2026
Estimate forQ4 25(Revenue/ EPS)
$118.75M
/
$0.08
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+6.61%
/
+33.33%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
+22.03%
/
-120.51%
Artivion, Inc. earnings per share and revenue
On 06. Nov. 2025, AORT reported earnings of 0.06 USD per share (EPS) for Q3 25, beating the estimate of 0.01 USD, resulting in a 242.86% surprise. Revenue reached 111.39 million, compared to an expected 112.65 million, with a -1.12% difference. The market reacted with a -5.54% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of 0.08 USD, with revenue projected to reach 118.75 million USD, implying an increase of 33.33% EPS, and increase of 6.61% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
What were Artivion, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Artivion, Inc. reported EPS of $0.06, beating estimates by 242.86%, and revenue of $111.39M, -1.12% below expectations.
How did the market react to Artivion, Inc.'s Q3 2025 earnings?
The stock price moved down -5.54%, changed from $47.50 before the earnings release to $44.87 the day after.
When is Artivion, Inc. expected to report next?
The next earning report is scheduled for 23. Feb. 2026.
What are the forecasts for Artivion, Inc.'s next earnings report?
Based on 9
analysts, Artivion, Inc. is expected to report EPS of $0.08 and revenue of $118.75M for Q4 2025.